Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00052156
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2003-01-23
Brief Title:
Vaccine Therapy for Patients With Stage IV Melanoma
Sponsor:
CancerVax Corporation
Organization:
CancerVax Corporation
Study Overview
Official Title:
A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine CancerVax Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma
Status:
UNKNOWN
Status Verified Date:
2005-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase III study in patients with melanoma that has spread to the lymph nodes andor a distant organ and who have had all of their cancer surgically removed The purpose of this study is to evaluate the ability of the CancerVax vaccine to prevent or slow the recurrence of melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| JWCI-MC-4-001 | None | None | None |